SIPONIMOD Drug Patent Profile

Which patents cover Siponimod, and what generic alternatives are available?

Siponimod is a drug marketed by Aurobindo Pharma Ltd and Riconpharma Llc and is included in two NDAs.

The generic ingredient in SIPONIMOD is siponimod. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the siponimod profile page.

Summary for SIPONIMOD

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	51
Clinical Trials:	10
Patent Applications:	647
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SIPONIMOD
DailyMed Link:	SIPONIMOD at DailyMed

Recent Clinical Trials for SIPONIMOD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis	PHASE2
Arizona State University	PHASE2
St. Joseph's Hospital and Medical Center, Phoenix	PHASE2

See all SIPONIMOD clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for SIPONIMOD

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

L04AE	Sphingosine-1-phosphate (S1P) receptor modulators
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for SIPONIMOD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MAYZENT	Tablets	siponimod	0.25 mg, 1 mg and 2 mg	209884	5	2023-03-27

US Patents and Regulatory Information for SIPONIMOD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	SIPONIMOD	siponimod	TABLET;ORAL	218459-001	Mar 6, 2026		DISCN	No	No
Riconpharma Llc	SIPONIMOD	siponimod	TABLET;ORAL	218444-001	Apr 22, 2025		DISCN	No	No
Aurobindo Pharma Ltd	SIPONIMOD	siponimod	TABLET;ORAL	218459-002	Mar 6, 2026		DISCN	No	No
Aurobindo Pharma Ltd	SIPONIMOD	siponimod	TABLET;ORAL	218459-003	Mar 6, 2026		DISCN	No	No
Riconpharma Llc	SIPONIMOD	siponimod	TABLET;ORAL	218444-003	Apr 22, 2025		DISCN	No	No
Riconpharma Llc	SIPONIMOD	siponimod	TABLET;ORAL	218444-002	Apr 22, 2025		DISCN	No	No

Siponimod Market Dynamics and Financial Trajectory

Last updated: August 16, 2026

Siponimod, marketed by Novartis as Mayzent, has established a specialized position in active secondary progressive multiple sclerosis (SPMS). Its commercial performance depends on a narrow but clinically important population, long-term treatment persistence, pharmacogenetic testing, and competition from high-efficacy multiple sclerosis therapies. Revenue growth has been slower than the expansion of newer anti-CD20 products, but Mayzent retains defensible value through its first-in-class positioning in active SPMS and a patent estate that delays conventional generic competition.

What is siponimod and which patients does it treat?

Siponimod is an oral, once-daily sphingosine-1-phosphate receptor modulator. It selectively modulates S1P1 and S1P5 receptors and is approved for adults with relapsing forms of multiple sclerosis, including active SPMS in the United States. The FDA approved Mayzent in March 2019 based primarily on the phase 3 EXPAND trial.[1]

The commercial target population is narrower than the broader relapsing multiple sclerosis market. Patients generally have:

• Secondary progressive disease with clinical relapses or MRI activity
• Evidence of disability progression
• A need for an oral disease-modifying therapy
• A CYP2C9 genotype compatible with siponimod treatment

The FDA label excludes patients with a CYP2C9 3/3 genotype because of higher exposure and safety risk. Genotype testing is required before treatment, creating an additional prescribing step compared with several competing multiple sclerosis therapies.[2]

What did the EXPAND trial show?

EXPAND enrolled patients with SPMS and demonstrated a statistically significant reduction in three-month confirmed disability progression. Siponimod reduced the risk of confirmed disability progression by approximately 21% versus placebo in the primary analysis population.[3]

The clinical positioning is strongest in active SPMS. Evidence is less commercially differentiated in non-active progressive disease, where the absence of relapses or MRI activity reduces the rationale for an immunomodulatory treatment and complicates reimbursement.

How large is the siponimod market?

The addressable market is the active SPMS segment rather than all multiple sclerosis patients. Epidemiological estimates vary, but secondary progressive disease represents a substantial minority of the global MS population. The commercially treatable subset is smaller because patients must have active disease, adequate organ function, acceptable infection risk, and a suitable CYP2C9 genotype.

The market has four economic layers:

Market layer	Commercial relevance
Relapsing multiple sclerosis	Large market, but Mayzent competes with more established therapies
Active SPMS	Core Mayzent opportunity and strongest clinical differentiation
Non-active SPMS	Limited role because evidence and reimbursement are less favorable
Progressive MS generally	Large unmet need, but difficult to convert into treated demand

Mayzent benefits from being one of the few approved therapies specifically associated with active SPMS. Its limitation is that active SPMS is a smaller and more heterogeneous market than relapsing MS.

What is the financial trajectory for Mayzent?

Novartis reports Mayzent sales within its Innovative Medicines product disclosures. The product achieved rapid initial uptake after its 2019 launch, followed by a more mature growth profile as physicians adopted competing oral and infused therapies.

Public company reporting indicates the following broad trajectory:

Period	Financial pattern	Main driver
2019	Launch phase	Initial US and international commercialization
2020-2021	Rapid expansion	New diagnosis, treatment switching, and active-SPMS adoption
2022-2023	Maturing growth	Increasing competition and narrower eligible population
2024 onward	Mature-product phase	Persistence, international demand, and pricing offset competitive pressure

Novartis has not positioned Mayzent as a growth engine on the scale of Kesimpta, Pluvicto, or Kisqali. The company’s multiple sclerosis strategy has shifted toward Kesimpta, while Mayzent remains a focused specialty product.

What factors support Mayzent revenue?

Revenue is supported by four factors.

First, Mayzent has a differentiated label in active SPMS. Physicians treating patients with documented progression and ongoing inflammatory activity may view it as a direct fit rather than a general-purpose relapsing-MS product.

Second, once-daily oral dosing supports treatment persistence and avoids infusion-center administration. This can be commercially useful in community neurology practices and for patients who prefer oral therapy.

Third, the disease has chronic treatment economics. A patient who remains on therapy can generate recurring annual revenue, subject to payer access, discontinuation, safety monitoring, and disease progression.

Fourth, Novartis has an established neurology infrastructure and payer contracting capability. The same commercial organization that supports other multiple sclerosis products can improve specialist reach and patient-support enrollment.

What factors limit revenue?

The main constraint is patient selection. Mayzent is not a broad replacement for first-line relapsing-MS therapies. It targets a narrower population with progression and disease activity.

The product also faces:

• CYP2C9 testing requirements
• First-dose and cardiac monitoring considerations in selected patients
• Infection and macular-edema risk
• Competition from high-efficacy anti-CD20 antibodies
• Pressure from lower-cost oral therapies
• Physician preference for therapies with longer-established safety and utilization data
• Limited evidence in non-active progressive disease

The commercial consequence is a product with durable specialty revenue potential but a lower ceiling than broad multiple sclerosis franchises.

How does siponimod compare with competing multiple sclerosis drugs?

Mayzent versus Kesimpta

Kesimpta, Novartis’ ofatumumab, has a much broader relapsing-MS opportunity and stronger growth profile. Kesimpta is a high-efficacy anti-CD20 therapy administered subcutaneously, while Mayzent is an oral S1P modulator with a more specific active-SPMS positioning.

Kesimpta is strategically more important to Novartis because its eligible population is substantially larger. Mayzent remains relevant where oral administration, active SPMS, or avoidance of B-cell depletion influences treatment selection.

Mayzent versus Ocrevus

Ocrevus, Roche’s ocrelizumab, has a broad relapsing-MS indication and is also approved for primary progressive MS. It has a larger commercial base and greater physician familiarity. Mayzent competes more directly in progressive disease only when the patient has active SPMS and an oral treatment is preferred.

Mayzent versus Zeposia

Zeposia, Bristol Myers Squibb’s ozanimod, is another oral S1P receptor modulator. It is approved for relapsing forms of MS and ulcerative colitis, giving it a broader commercial platform. Mayzent has stronger positioning in active SPMS, while Zeposia benefits from a second major indication and a broader relapsing-MS label.

Mayzent versus Mavenclad

Mavenclad, marketed by Merck KGaA, uses a short-course immune-reconstitution approach rather than continuous daily dosing. Some physicians and patients prefer intermittent treatment, especially when adherence to daily therapy is a concern. Mayzent offers continuous oral suppression and a more conventional maintenance model.

Product	Company	Administration	Core MS positioning	Main commercial advantage
Mayzent	Novartis	Daily oral	Active SPMS and relapsing MS	Specific active-SPMS positioning
Kesimpta	Novartis	Monthly subcutaneous	Relapsing MS	High efficacy and broad population
Ocrevus	Roche	Intravenous infusion	Relapsing and primary progressive MS	Large evidence base and broad label
Zeposia	Bristol Myers Squibb	Daily oral	Relapsing MS	Oral therapy plus ulcerative colitis
Mavenclad	Merck KGaA	Short-course oral	Active relapsing MS	Intermittent dosing
Generic fingolimod	Multiple companies	Daily oral	Relapsing MS	Lower price after loss of exclusivity

When does siponimod lose exclusivity?

Mayzent faces two distinct exclusivity questions: regulatory exclusivity and patent protection.

The FDA approved Mayzent in 2019 under the New Molecular Entity pathway. NME exclusivity generally lasts five years, placing the basic US regulatory exclusivity period in 2024, subject to statutory extensions and the timing of abbreviated new drug applications. That period is separate from patent protection.[4]

The principal patent estate is expected to provide longer protection than the original NME period. Public patent records identify composition-of-matter and related patents covering siponimod and its use. The key US protection is generally reported to extend into the early 2030s, subject to patent-term adjustment, terminal disclaimers, pediatric extensions, and the scope of Orange Book listings.

What patents protect siponimod?

The Mayzent estate is built around several patent categories:

1. Composition-of-matter patents covering siponimod and related chemical compounds.
2. Pharmaceutical-composition patents covering dosage forms and excipients.
3. Method-of-treatment patents covering multiple sclerosis and progressive disease.
4. Genotype-related or dosing patents associated with CYP2C9-directed treatment.
5. Manufacturing and process patents, where applicable.

Composition-of-matter protection is the most important barrier because it can block ordinary generic substitution even if formulation or method patents are challenged. Formulation and method-of-use patents can still support litigation and labeling restrictions after a core compound patent expires.

What is the Orange Book status of Mayzent?

Mayzent is an FDA-approved small-molecule drug and is eligible for Orange Book patent listings. Generic applicants seeking approval before listed patent expiration can file Paragraph IV certifications against relevant patents.

The practical generic-entry question is not whether a single Mayzent patent exists. It is whether a generic applicant can obtain approval by:

• Waiting for the core patent to expire
• Challenging the compound patent
• Carving out patented methods from the label
• Designing around formulation claims
• Accepting litigation risk under the Hatch-Waxman framework

A generic could pursue a label that excludes patented uses if the remaining unpatented indications support commercial value. That strategy is more difficult when active SPMS represents the principal commercial use.

Which companies are challenging siponimod patents?

Publicly visible generic competition has been less developed than for older MS drugs such as fingolimod. The principal potential challengers are large generic manufacturers and specialty pharmaceutical companies with experience in Paragraph IV litigation and complex oral products.

A credible challenger would need to address:

• Bioequivalence
• S1P receptor pharmacology
• CYP2C9 genotype restrictions
• Dose titration
• Cardiac safety
• Food-effect and exposure requirements
• Patent claims covering active ingredients, formulations, and methods

No biosimilar pathway applies. Siponimod is a chemically synthesized small molecule, so competition would proceed through the ANDA pathway rather than the biologics license application pathway.

What generic entry risks exist for Mayzent?

The risk is low in the near term and rises as early-2030s patent dates approach. A successful Paragraph IV challenge could accelerate entry, but the commercial opportunity may be less attractive than the opportunity for a broad relapsing-MS product.

Potential launch scenarios are:

Scenario	Timing	Market effect
No successful challenge	After core patent expiry	Gradual generic erosion
Paragraph IV settlement	Before patent expiry	Delayed launch under negotiated terms
Successful invalidity or non-infringement decision	Before expiry	Rapid price and volume pressure
Label carve-out	Before full patent expiry	Limited generic share, focused on unpatented uses
Authorized generic	At or near loss of exclusivity	Controlled erosion of branded revenue

Generic erosion would likely be fastest in price-sensitive markets and slower in markets where neurologist prescribing, reimbursement restrictions, or genotype testing create switching friction.

What patent litigation and settlement risks affect Mayzent?

A Mayzent patent dispute would likely follow the standard Hatch-Waxman sequence: ANDA filing, Paragraph IV notice, a 45-day period for suit, and a potential 30-month stay of FDA approval under applicable conditions.[5]

The most important litigation variables are:

• Whether the asserted patent covers the active ingredient or only a use
• Whether the generic label includes active SPMS
• The strength of written-description and enablement defenses
• Patent-term-adjustment calculations
• The commercial value of a restricted label
• The willingness of Novartis to settle before the core patent expires

A settlement could provide a licensed launch date, but the economic terms would depend on the strength of the challenged patent, the number of challengers, and the expected value of Mayzent sales at the settlement date.

What is the FDA regulatory status of siponimod?

The FDA approved Mayzent on March 26, 2019, for adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1]

Regulatory requirements that affect commercialization include:

• CYP2C9 genotype testing
• Dose titration
• Cardiac assessment for selected patients
• Liver-function and ophthalmic monitoring in applicable patients
• Infection-risk management
• Pregnancy and fetal-risk controls

The regulatory profile is established, but monitoring requirements create friction relative to injectable or oral competitors with simpler initiation procedures.

How strong is the siponimod patent estate?

The estate is moderately strong commercially because it combines an early-maturing specialty market with compound protection extending beyond initial regulatory exclusivity. Its strength is highest if the core composition patent remains enforceable through the early 2030s.

The estate is less secure against:

• A successful invalidity challenge to the composition patent
• A generic carve-out that excludes active-SPMS methods
• Independent formulation development
• Patent-term disputes
• Competition from non-infringing therapies rather than direct generics

Patent strength should therefore be separated from revenue strength. Mayzent can retain patent protection while losing share to Kesimpta, Ocrevus, Zeposia, or other branded treatments.

What licensing deals support siponimod commercialization?

Novartis is the principal global commercial owner and marketer of Mayzent. The product originated from the company’s internal pharmaceutical research and development portfolio rather than a widely disclosed external licensing transaction.

Novartis’ most important commercial advantage is portfolio integration. Mayzent can be marketed alongside Kesimpta and other neurology products, although this creates internal capital-allocation pressure because Kesimpta has the broader growth opportunity.

No major publicly disclosed co-commercialization transaction currently defines Mayzent’s global strategy. Regional distribution, reimbursement, and local regulatory arrangements may exist without changing global ownership economics.

What is the revenue exposure from Mayzent?

Mayzent is material to Novartis’ neuroscience portfolio but not central to the company’s consolidated revenue base. The company’s financial exposure is concentrated in:

• Active-SPMS patient retention
• Net price after payer rebates
• International reimbursement
• Competition from anti-CD20 drugs
• Patent timing
• Generic launch sequence

The product is more valuable as a durable specialty franchise than as a high-growth asset. A stable annual revenue base could remain attractive if operating costs are controlled, but declining patient starts or accelerated generic entry would reduce its strategic value.

Key Takeaways

• Siponimod is a differentiated oral therapy for active SPMS and relapsing forms of multiple sclerosis.
• Mayzent’s strongest commercial position is in patients with progressive disease and ongoing inflammatory activity.
• Revenue growth has matured as Novartis prioritizes Kesimpta and faces competition from Ocrevus, Zeposia, Mavenclad, and other high-efficacy therapies.
• CYP2C9 testing and treatment-monitoring requirements restrict the eligible market and add prescribing friction.
• Mayzent is a small-molecule drug, so biosimilar competition does not apply.
• The core patent estate is generally expected to extend into the early 2030s, although exact entry timing depends on listed patents, patent-term calculations, and Paragraph IV litigation.
• Generic erosion is likely to be gradual if the core composition patent survives, but could accelerate after a successful challenge.
• The principal commercial risk is branded competition before patent expiry, not only generic substitution after expiry.

Frequently Asked Questions

Is siponimod considered a high-efficacy multiple sclerosis therapy?

Siponimod is an effective disease-modifying therapy with evidence in active SPMS, but treatment classification varies by physician and patient risk profile. Anti-CD20 therapies are more commonly positioned as high-efficacy options for broad relapsing MS.

Does siponimod require genetic testing?

Yes. CYP2C9 genotype testing is required before treatment because genotype affects siponimod metabolism, exposure, and dosing eligibility.

Can a generic manufacturer avoid Mayzent method-of-use patents?

Potentially. An ANDA applicant may seek a label carve-out excluding patented indications, but the commercial value of that strategy depends on which uses remain available and whether compound or formulation patents also apply.

Is Mayzent approved for primary progressive multiple sclerosis?

No. Mayzent is not approved for primary progressive MS. Its progressive-disease positioning is active secondary progressive MS.

What is the main long-term threat to Mayzent revenue?

The main long-term threat is competitive substitution by broader, high-efficacy therapies, particularly anti-CD20 products. Generic entry becomes a larger threat as early-2030s patent protection approaches.

References

1. U.S. Food and Drug Administration. (2019, March 26). FDA approves new oral drug to treat multiple sclerosis. https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-drug-treat-multiple-sclerosis

2. U.S. Food and Drug Administration. (2024). Mayzent (siponimod) prescribing information. Novartis Pharmaceuticals Corporation. https://www.accessdata.fda.gov/drugsatfda_docs/label/

3. Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Moseley, F. L., Zhang, Y., Hotermans, C., & EXPAND Clinical Investigators. (2018). Siponimod versus placebo in secondary progressive multiple sclerosis: A double-blind, randomised, phase 3 study. The Lancet, 391(10127), 1263-1273. https://doi.org/10.1016/S0140-6736(18)30475-6

4. U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions for new drug product exclusivity. https://www.fda.gov/drugs/development-resources/new-drug-product-exclusivity

5. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-refuse-receive-standards

6. Novartis AG. (2024). Annual report 2023. https://www.novartis.com/investors/financial-data/annual-reporting

7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/ <|endoftext|>